Prokidney reports second quarter 2025 financial results and provides regulatory and clinical updates

Winston-salem, n.c., aug. 12, 2025 (globe newswire) -- prokidney corp. (nasdaq: prok) (“prokidney” or the “company"), a leading late clinical-stage cell therapeutics company focused on chronic kidney disease (ckd), today reported financial results for the second quarter ended june 30, 2025, and provided regulatory and clinical updates.

PROK Ratings Summary

PROK Quant Ranking